Literature DB >> 31507238

Clinical and microbiological factors associated with mortality in candidemia in adult patients 2007-2016.

Mari Ala-Houhala1, Miia Valkonen2, Elina Kolho1, Nathalie Friberg3, Veli-Jukka Anttila1.   

Abstract

Background: Candidemia is a life-threatening infection with high mortality. Our aim was to evaluate the Candida species distribution, antifungal susceptibilities and risk factors associated with 30-day mortality in candidemia in Southern Finland.
Methods: We present a retrospective analysis of candidemia cases from the hospital district of Helsinki and Uusimaa during 2007-2016. Patients younger than 18 years old were excluded. A total of 386 candida isolates from 374 episodes of candidemia were identified in 350 adult patients.
Results: Candida albicans was the leading cause of candidemia (60.4%), followed by C. glabrata (21.5%), C. parapsilosis (5.2%) and C. dubliniensis (5.2%). There was no statistically significant change in the distribution of C. albicans vs non-albicans species during the study period. Thirty-day overall mortality was 30.7%. When patients who received no antifungal treatment were excluded from the mortality analysis, 30-day mortality was 23.0%. Severity of underlying illnesses (OR 20.55, 95% CI 5.98-70.60), ICU stay at the onset of candidemia (OR 5.06, 95% CI 1.75-14.68) and age >65 years (OR 3.98, 95% CI 1.97-8.02) were independent risk factors of 30-day mortality in multivariable analysis. However, there was no statistically significant association between 30-day mortality and an early start of an effective antifungal.
Conclusion: There was not a significant shift to non-albicans species as the cause of candidemia in Southern Finland during the 10-year study period. Furthermore, we did not find an association between 30-day mortality and the early start of an antifungal treatment. Comorbidity considerably increased the risk of fatal outcome.

Entities:  

Keywords:  30-day mortality; Candidemia; early start of treatment; risk factors; species distribution

Mesh:

Substances:

Year:  2019        PMID: 31507238     DOI: 10.1080/23744235.2019.1662941

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  6 in total

Review 1.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.

Authors:  Amir Arastehfar; Toni Gabaldón; Rocio Garcia-Rubio; Jeffrey D Jenks; Martin Hoenigl; Helmut J F Salzer; Macit Ilkit; Cornelia Lass-Flörl; David S Perlin
Journal:  Antibiotics (Basel)       Date:  2020-12-08

2.  Predominance of Candida Glabrata among Non-albicans Candida Species in a 16-Year Study of Candidemia at a Tertiary Care Center in Lebanon.

Authors:  Aline El Zakhem; Rachid Istambouli; Maria Alkozah; Amal Gharamti; Mohamad Ali Tfaily; Jean-Francois Jabbour; George F Araj; Hani Tamim; Souha S Kanj
Journal:  Pathogens       Date:  2021-01-19

3.  Development and Application of a Multiple Cross Displacement Amplification Combined With Nanoparticle-Based Lateral Flow Biosensor Assay to Detect Candida tropicalis.

Authors:  Yu Wang; Xue Zhao; Jinzhi Cheng; Xiaomin Tang; Xu Chen; Honglan Yu; Shijun Li
Journal:  Front Microbiol       Date:  2021-06-10       Impact factor: 5.640

4.  A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China.

Authors:  Zhangrui Zeng; Yinhuan Ding; Gang Tian; Kui Yang; Jian Deng; Guangrong Li; Jinbo Liu
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-14       Impact factor: 4.887

5.  Screening the Drug:H+ Antiporter Family for a Role in Biofilm Formation in Candida glabrata.

Authors:  Rui Santos; Mafalda Cavalheiro; Catarina Costa; Azusa Takahashi-Nakaguchi; Michiyo Okamoto; Hiroji Chibana; Miguel C Teixeira
Journal:  Front Cell Infect Microbiol       Date:  2020-02-04       Impact factor: 5.293

6.  Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Mohammadreza Salehi; Melike Yaşar; Tuğrul Hoşbul; Macit Ilkit; Weihua Pan; Ferry Hagen; Nazlı Arslan; Hatice Türk-Dağı; Süleyha Hilmioğlu-Polat; David S Perlin; Cornelia Lass-Flörl
Journal:  Mycoses       Date:  2020-08-05       Impact factor: 4.377

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.